Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital ...
Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...
BMS got its hands on KarXT through its $14 billion buyout of Karuna Therapeutics last December. According to analysts at William Blair, Cobenfy in the U.S. could achieve sales of roughly $2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback